Nura Bio

aid: nura-bio
name: Nura Bio
description: Nura Bio, Inc. is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California,
  developing neuroprotective small-molecule medicines that halt neurodegeneration before it progresses. Conceived in 2018
  by The Column Group together with scientific founders Steve McKnight, PhD and Marc Freeman, PhD, the company targets SARM1
  — a neuronally enriched NAD hydrolase that acts as an axon-intrinsic metabolic sensor and central driver of axonal degeneration
  — on the thesis that intervening early in that pathway confers durable structural and functional neuroprotection across
  peripheral, central and ocular nervous-system disorders. Its pipeline is led by NB-4746, a first-generation oral, brain-penetrant,
  reversible orthosteric SARM1 inhibitor in a global Phase 1b/2a study in ALS, and NB-9402, a mechanistically differentiated
  second-generation oral, covalent, irreversible, allosteric inhibitor completing a Phase 1a healthy-volunteer study in 2026.
  Nura Bio launched publicly in January 2020 with a $73 million Series A, extended that round with $68 million to pass $140
  million raised, and closed a $73.8 million Series B in June 2026 led by The Column Group with Euclidean Capital, Samsara
  BioCapital and Sanofi Ventures; Shilpa Sambashivan, PhD, a co-founder and its chief scientist, serves as CEO. Its science
  is published in NEURON and CELL REPORTS. Nura Bio runs no developer program and publishes no product API, developer portal,
  API reference, SDK or pricing. The only machine-readable surfaces reachable without credentials are a published llms.txt
  and the WordPress REST content API behind nurabio.com, which serves the news archive, site pages, people directory and media
  library as JSON — both catalogued here.
deliveryModel:
  model: saas
  open_source: false
  commercial: true
  callable_host: true
  label: Hosted service · you call their endpoint
  confidence: high
  source:
  - openapi
  - pricing
  generated: '2026-08-28'
  method: derived
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  probe_state: covered
  source:
  - authentication
  - rate-limits
  - security
  generated: '2026-09-03'
  method: derived
image: https://nurabio.com/wp-content/uploads/2020/07/NuraBio_full_logo_grey_TM-1-1-1030x167.png
url: https://raw.githubusercontent.com/api-evangelist/nura-bio/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: profiled
x-tier-reason: enrichment-pipeline
specificationVersion: '0.20'
created: '2026-08-26'
modified: '2026-08-26'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Neuroscience
- Neurodegeneration
- Drug Discovery
- Life Sciences
- Clinical Trials
- Rare Disease
- Small Molecule Therapeutics
- content-api
tags_raw:
- Company
- biotechnology
- pharmaceuticals
- neuroscience
- neurodegeneration
- drug-discovery
- life-sciences
- clinical-trials
- rare-disease
- small-molecule-therapeutics
- content-api
apis:
- aid: nura-bio:nurabio-com-website-wordpress-rest
  name: Nura Bio Website (WordPress REST)
  description: 'The public WordPress REST API (wp-json) of the Nura Bio website at nurabio.com: the route index of the site''s
    content management system, catalogued as one site surface rather than as separate APIs.'
  baseURL: https://nurabio.com/wp-json
  tags:
  - WordPress
  x-surface: platform-generated
  properties:
  - type: Documentation
    url: https://nurabio.com/wp-json
  x-platform: wordpress
  x-platform-surface: rest
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Website
  url: https://nurabio.com/
- type: About
  url: https://nurabio.com/about-us/
- type: Science
  url: https://nurabio.com/our-science/
- type: News
  url: https://nurabio.com/news-and-literature/
- type: BlogRSS
  url: https://nurabio.com/feed/
- type: Careers
  url: https://nurabio.com/join-us/
- type: ContactForm
  url: https://nurabio.com/contact/
- type: LinkedIn
  url: https://www.linkedin.com/company/nurabio
- type: LLMsTxt
  url: llms/nura-bio-llms.txt
- type: Authentication
  url: authentication/nura-bio-authentication.yml
- type: Conventions
  url: conventions/nura-bio-conventions.yml
- type: Conformance
  url: conformance/nura-bio-conformance.yml
- type: ErrorCatalog
  url: errors/nura-bio-problem-types.yml
- type: Lifecycle
  url: lifecycle/nura-bio-lifecycle.yml
- type: DataModel
  url: data-model/nura-bio-data-model.yml
- type: RateLimits
  url: rate-limits/nura-bio-rate-limits.yml
- type: Plans
  url: plans/nura-bio-plans-pricing.yml
- type: Packages
  url: packages/nura-bio-packages.yml
- type: DomainSecurity
  url: security/nura-bio-domain-security.yml
- type: AgentSkill
  url: skills/_index.yml
x-enrichment:
  date: '2026-08-26'
  status: enriched
  artifacts_added: 20
  pass: local-v1
x-coverage:
  state: covered
  reason: no-machine-readable-spec
  detail: 'Nura Bio is a clinical-stage biopharmaceutical company with no developer program, no product API and no published
    OpenAPI, but STEP 0b contract discovery did not come back empty: nurabio.com serves a 200 llms.txt and a 269-route WordPress
    REST index at /wp-json/, from which a 24-operation read-only content API was derived and verified live.'
  evidence:
  - url: https://nurabio.com/wp-json/
    status: 200
  - url: https://nurabio.com/llms.txt
    status: 200
  - url: https://nurabio.com/openapi.json
    status: 404
  - url: https://nurabio.com/.well-known/agent-card.json
    status: 404
  - url: https://nurabio.com/wp-json/mcp/mcp-adapter-default-server
    status: 404
  checked: '2026-08-26'